continuous glucose monitor

Overview

A continuous glucose monitor (CGM) is a wearable glucose-sensing technology used to measure interstitial glucose levels repeatedly over time, providing a dense glucose profile rather than isolated point measurements. In clinical practice, CGM is used to support diabetes management by helping patients and clinicians identify patterns of hyperglycemia and hypoglycemia, assess glycemic variability, and evaluate metrics such as time-in-range, time-above-range, and time-below-range.

CGM has become an important tool in the management of type 1 diabetes and is increasingly studied in type 2 diabetes, including in people treated with basal insulin, Insulin Therapy, and modern therapies. It is also being explored in other metabolic and endocrine contexts, such as cystic fibrosis-related diabetes, glycogen storage disease, post-bariatric hypoglycemia, and in people without diabetes for research on early dysglycemia and personalized nutrition. Recent work also links CGM with automated insulin delivery systems, hybrid closed-loop systems, fully closed-loop insulin delivery, and CGM-integrated digital health apps, reflecting its central role in contemporary diabetes technology.

Recent Publications Summary (latest 30 papers)

Recent publications on continuous glucose monitoring (CGM) in type 2 diabetes have focused on its role alongside Insulin Therapy, its implementation in routine care, and its broader clinical and real-world impact. A randomized, multicentre, open-label superiority trial evaluated real-time CGM versus self-monitoring of blood glucose in adults with type 2 diabetes managed with basal insulin and modern therapies, addressing the still-uncertain value of CGM in this population 42035781Apr. In parallel, a cost-effectiveness analysis compared automated insulin delivery with multiple daily injections plus CGM in insulin-treated adults with type 2 diabetes in the United States, reflecting ongoing interest in CGM as part of more advanced diabetes technology strategies 42086278May.

Other studies examined how CGM is used in practice and what affects uptake. In a primary care setting, investigators evaluated the impact of activating CGM alarms on CGM metrics in people with type 2 diabetes treated with insulin using the FSL2 system, focusing on whether alarm use was associated with achieved glycemic control 42049539Apr. A retrospective study of adults with type 2 diabetes receiving endocrinology care found that patient preference was the most common reason for CGM non-use, while undocumented CGM discussions were also frequent; financial and phone compatibility barriers were less common 41856330Mar. A real-world data report from European countries highlighted the importance of observational evidence for understanding diabetes technology use, including CGM, under everyday conditions and identifying practical hurdles to adoption and sustained use 41933491Apr.

Beyond glycemic management, CGM has also been explored in relation to diabetes complications. One study specifically noted that the relationship between CGM and corneal neuropathy measured by in vivo confocal microscopy in type 2 diabetes remains unclear, indicating an emerging but unresolved area of investigation 41606797Jan.

What Changes, What Holds

1. CGM’s role in type 2 diabetes is still being defined, especially alongside insulin treatment
NEW DIRECTION Real-time CGM is being tested against usual glucose self-monitoring in adults with type 2 diabetes on basal insulin and modern therapies, which matters because the Overview already says CGM is increasingly studied in type 2 diabetes but does not settle how strongly it should be recommended in this subgroup 42035781Apr. The accompanying cost-effectiveness work suggests the field is moving toward technology-strategy comparisons rather than simple device-versus-device questions 42086278May.

2. Uptake depends as much on workflow and preference as on device performance
NEW DIRECTION Activating alarms, documenting discussions, and addressing patient preference emerge as practical determinants of CGM use in routine care, so the main issue is no longer only whether CGM improves glycemic metrics but whether it is actually adopted and sustained in everyday type 2 diabetes management 42049539Apr41856330Mar. The real-world European report reinforces that implementation barriers and observational evidence matter for understanding how CGM functions outside trials 41933491Apr.

3. CGM is now being linked to diabetes complications, but that role remains unsettled
NEW DIRECTION Investigation of corneal neuropathy moves CGM beyond glycemic tracking into complication-related phenotyping, a role the Overview does not cover. The finding does not overturn established uses; instead, it signals an emerging research direction in which CGM may be studied as part of complication assessment or risk stratification, though the relationship remains unclear and needs direct validation 41606797Jan.

Overview update candidates: CGM in type 2 diabetes remains an active area of evaluation alongside Insulin Therapy and modern treatments; practical barriers and alarm use affect real-world uptake; links to diabetes complications such as corneal neuropathy are emerging but not established.